ObsEva SA (NASDAQ:OBSV) has been given a $27.00 target price by analysts at HC Wainwright in a research note issued to investors on Wednesday. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 251.33% from the stock’s current price.

A number of other brokerages have also issued reports on OBSV. Zacks Investment Research upgraded ObsEva SA from a “sell” rating to a “hold” rating in a research note on Tuesday, May 30th. Credit Suisse Group reiterated an “outperform” rating and issued a $27.00 price target on shares of ObsEva SA in a research note on Tuesday, April 18th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $24.00.

Shares of ObsEva SA (NASDAQ OBSV) opened at 7.685 on Wednesday. The company’s market cap is $204.60 million. The company’s 50-day moving average price is $7.89 and its 200 day moving average price is $9.12. ObsEva SA has a 1-year low of $5.00 and a 1-year high of $14.70.

ObsEva SA (NASDAQ:OBSV) last issued its quarterly earnings results on Tuesday, August 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.13. During the same period last year, the firm posted ($0.30) earnings per share. On average, analysts predict that ObsEva SA will post ($2.04) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/08/16/obseva-sa-obsv-pt-set-at-27-00-by-hc-wainwright.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. NEA Management Company LLC bought a new position in ObsEva SA during the first quarter valued at approximately $34,734,000. Sphera Funds Management LTD. bought a new position in ObsEva SA during the first quarter valued at approximately $2,197,000. VHCP Management II LLC bought a new position in ObsEva SA during the second quarter valued at approximately $1,283,000. Sectoral Asset Management Inc increased its position in ObsEva SA by 181.9% in the second quarter. Sectoral Asset Management Inc now owns 212,831 shares of the company’s stock valued at $1,820,000 after buying an additional 137,331 shares during the period. Finally, UBS Oconnor LLC bought a new position in ObsEva SA during the first quarter valued at approximately $1,017,000. 49.11% of the stock is owned by institutional investors and hedge funds.

About ObsEva SA

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.